SARC Sarcoma SPORE

SARC肉瘤孢子

基本信息

批准号：
8551649
负责人：
RAPHAEL E. POLLOCK
金额：
$ 215.05万
依托单位：
SARC
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-26 至 2017-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8551649
关键词：
Accounting Automobile Driving Biological Biological Markers Biological Process Biometry Cancer Biology Cancer Center Cell Line Cessation of life Clinical Clinical Research Clinical Trials Collaborations Complex Databases Development Diagnostic Discipline Disease Distant Early Diagnosis Epithelial Evaluation Ewings sarcoma Future G-Protein-Coupled Receptors Genetic Genetic Engineering Goals Head and neck structure Health Human Image Individual Institution Intervention Intramural Research Program Investigation Knowledge Laboratories Lead Light Location Lung Malignant Neoplasms Malignant Peripheral Nerve Sheath Tumor Measures Medical Oncology Mesenchymal Cell Neoplasm Metastatic Neoplasm to the Lung Metastatic/Recurrent Michigan Molecular Necrosis Neoplasm Metastasis Nonprofit Organizations Operative Surgical Procedures Outcome Paraffin Tissue Pathology Patients Pediatric Oncology Pharmaceutical Preparations Phase Pilot Projects Positron-Emission Tomography Prevention Process Radiation Oncology Radiation therapy Radiosurgery Recurrence Research Research Infrastructure Research Personnel Research Project Grants Resources Retroperitoneal Space Secure Signaling Pathway Gene Site Specialist Surgical Oncology Surgical margins Survival Rate Testing Therapeutic Tissue Microarray Tissues Toxic effect Translational Research Translations Universities Validation Xenograft procedure base career chemotherapy clinically relevant cost experience improved in vivo Model innovation irradiation mortality new therapeutic target novel novel therapeutic intervention osteosarcoma performance site pre-clinical programs response sarcoma scaffold soft tissue therapeutic target treatment strategy tumor

项目摘要

DESCRIPTION (provided by applicant): This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS; 2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor; 3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma; and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning; 2) Tissue and Pathology; 3) Clinical Trials; and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances.

描述（由申请人提供）：本申请代表了优秀机构，主要肉瘤专用非营利组织和NCI内部壁内计划之间前所未有的合作。该孢子源自SARC，SARC是一个非营利性财团，促进了国家卓越中心在肉瘤中的研究。 Sarc肉瘤孢子的主要目标是将生物学和技术进步的转化为预防，诊断，预后预测指标，尤其是 - 肉瘤治疗方面的进步。 SARC肉瘤孢子由SARC，哈佛大学，医学博士Anderson癌症中心和NCI壁内计划的多个研究人员锚定，但还包括来自斯坦福大学，哥伦比亚大学和密歇根大学的主要个人研究人员。研究人员代表医学和小儿肿瘤学，项目探索软组织和骨肉瘤。提出了四个主要项目：1）基于HDACI的遗传复杂ST治疗的治疗策略； 2）鉴定与NFI相关的恶性外周神经鞘肿瘤的治疗窗口； 3）研究G蛋白耦合受体是侵袭性疾病的生物标志物和Ewing肉瘤中新型治疗靶标的生物标志物； 4）开发定量成像生物标志物，用于使用PET和MRL中的先进方法评估对肉瘤治疗的治疗反应。这些项目由4个核心整合和支持：1）行政，评估和计划； 2）组织和病理； 3）临床试验； 4）生物统计学。孢子应用程序概述了一项发展研究计划，其中包括选择新项目的计划以及14个拟议的发展试点项目。我们还包括一项职业发展计划，概述了在转化或临床肉瘤研究中识别和支持年轻研究人员的机制。这些项目，核心和程序高度整合，并有望最大程度地利用孢子机制来实现转化目标。该孢子与最先进的研究项目一起，与律师事务所的多机构，协作实力以及领先的机构产生转化进展的承诺。